Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin
Loading...
Date
2011
Journal Title
Journal ISSN
Volume Title
Publisher
Journal of Antimicrobial Chemotherapy
Abstract
In resource-poor countries, HIV and tuberculosis (TB) co-infection results in significant morbidity and mortality. Co-treatment is recommended by the WHO;1 however, drug interactions are common between anti-TB regimens containing rifampicin and antiretroviral drugs. In these settings, rifampicin is a key drug for TB treatment because alternative rifamycins are more expensive and usually not available in public TB control programmes. Similarly, for HIV treatment, only a limited number of antiretroviral drugs are routinely used. The problems arising from limited drug options are compounded by the wide use of fixed-dose combination (FDC) formulations for both diseases. When these formulations are used, drug substitutions are not possible and dose adjustments are usually difficult.
Description
Keywords
PK, Antimycobacterial agents, HIV antiviral pharmacology
Citation
Lamorde, M., Byakika-Kibwika, P., Okaba-Kayom, V., Ryan, M., Coakley, P., Boffito, M., ... & Merry, C. (2011). Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. Journal of Antimicrobial Chemotherapy, 66(1), 180-183. doi:10.1093/jac/dkq411